• 1. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 2. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?
  Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873
• 3. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 4. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 5. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565

Professional Introduction to 1-Butyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (CAS No. 103854-71-3)

1-Butyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid, identified by the Chemical Abstracts Service Number (CAS No.) 103854-71-3, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the pyridazine class, a scaffold that is widely explored for its pharmacological potential due to its unique structural and electronic properties. The presence of a butyl group at the 1-position and a carboxylic acid moiety at the 3-position introduces specific functional characteristics that make this molecule of particular interest for further chemical modifications and biological evaluations.

The structural framework of 1-butyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid encompasses a six-membered ring consisting of two nitrogen atoms and four carbon atoms. The oxo group at the 6-position contributes to the compound's reactivity, enabling various chemical transformations that can be exploited in drug design. The carboxylic acid functionality at the 3-position not only influences the compound's solubility and stability but also provides a site for further derivatization, such as esterification or amidation, which can modulate its pharmacokinetic properties.

In recent years, there has been a growing interest in pyridazine derivatives as potential therapeutic agents. These compounds have been investigated for their activity in multiple biological pathways, including enzyme inhibition, receptor binding, and modulation of signal transduction processes. The specific substitution pattern of 1-butyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid makes it a promising candidate for further exploration in these areas. For instance, the butyl group can influence the compound's lipophilicity, which is a critical parameter in drug design as it affects membrane permeability and bioavailability.

One of the most compelling aspects of this compound is its potential as a lead structure for the development of novel pharmaceuticals. The pyridazine core is known to exhibit diverse biological activities, and modifications to this core can lead to compounds with enhanced potency and selectivity. Researchers have been particularly interested in its potential as an intermediate in the synthesis of more complex molecules with targeted pharmacological effects. The carboxylic acid group at the 3-position serves as a versatile handle for linking other functional groups or bioactive moieties, facilitating the creation of hybrid compounds that may exhibit synergistic effects.

Recent studies have highlighted the importance of understanding the conformational dynamics and electronic properties of heterocyclic compounds like 1-butyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid. Computational chemistry approaches, such as molecular modeling and density functional theory (DFT) calculations, have been employed to elucidate its three-dimensional structure and predict its interactions with biological targets. These studies have provided valuable insights into how structural modifications can influence binding affinity and metabolic stability. For example, computational analysis has suggested that optimizing the position and length of the butyl group can significantly enhance binding to specific enzymes or receptors.

The synthesis of 1-butyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid involves multi-step organic reactions that require careful optimization to ensure high yield and purity. Common synthetic routes include condensation reactions between appropriate precursors followed by functional group transformations to introduce the desired substituents. Advances in synthetic methodologies have enabled more efficient and scalable production processes, which are essential for both academic research and industrial applications.

In addition to its synthetic significance, 1-butyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid has been studied for its potential biological activities. Preliminary investigations have shown that derivatives of this compound may exhibit inhibitory effects on certain enzymes implicated in metabolic disorders or inflammatory diseases. The carboxylic acid group provides a site for interaction with metal ions or other biomolecules, which can be exploited to modulate enzyme activity or signal transduction pathways. Furthermore, the presence of nitrogen atoms in the ring system allows for hydrogen bonding interactions with biological targets, enhancing binding affinity.

The pharmaceutical industry has long recognized the importance of heterocyclic compounds in drug discovery due to their diverse biological activities and structural versatility. Pyridazines are no exception and have been incorporated into numerous marketed drugs across various therapeutic categories. The success of these drugs underscores the value of exploring new derivatives like 1-butyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid, which may serve as valuable building blocks for future therapeutics.

Future research directions may focus on exploring additional derivatives of this compound to optimize its pharmacological profile. Techniques such as high-throughput screening (HTS) could be employed to rapidly identify analogs with enhanced activity or reduced toxicity. Additionally, structure-based drug design approaches could be utilized to rationally modify the scaffold based on insights gained from computational modeling studies.

The role of 1-butyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid in medicinal chemistry extends beyond its use as an intermediate; it also represents an opportunity to investigate new chemical space for drug discovery. By leveraging its unique structural features and exploring diverse synthetic pathways, researchers can uncover novel therapeutic agents with improved efficacy and safety profiles.

• 100047-66-3(1-Methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)